OBJECTIVE: Recent evidence suggests that ghrelin, a peptidic hormone stimulating food intake, interacts with the dopamine signaling. This interaction has been demonstrated to modulate several effects of ghrelin, such as locomotor activity, memory, and food intake. Ghrelin increases dopamine levels in the shell of the nucleus accumbens stimulating food intake, while ablation of the ghrelin receptor attenuates the hypophagia caused by the activation of dopamine receptor 2. However, it is not known whether the orexigenic action of ghrelin is due to changes in central dopamine receptors. MATERIALS AND METHODS: We used Sprague-Dawley rats injected with different dopamine receptor agonists, antagonists, and ghrelin. RESULTS: We demonstrate that the specific central blockade of dopamine receptor 1, 2, and 3 (D1, D2, and D3, respectively) reduces the orexigenic action of ghrelin. Similarly, specific central stimulation, either singly of dopamine receptor 1 or dopamine receptors 2 and 3 simultaneously, causes a significant decrease in ghrelin-induced food intake. Co-stimulation of all three receptors (D1, D2, and D3) also led to a marked attenuation in ghrelin-induced food intake. Importantly, the reduction in ghrelin-induced feeding was not caused by malaise or any type of behavioral alteration. CONCLUSION: Taken together, these data indicate that dopamine receptors play an important role in acute stimulation of feeding behavior induced by central injection of ghrelin.
OBJECTIVE: Recent evidence suggests that ghrelin, a peptidic hormone stimulating food intake, interacts with the dopamine signaling. This interaction has been demonstrated to modulate several effects of ghrelin, such as locomotor activity, memory, and food intake. Ghrelin increases dopamine levels in the shell of the nucleus accumbens stimulating food intake, while ablation of the ghrelin receptor attenuates the hypophagia caused by the activation of dopamine receptor 2. However, it is not known whether the orexigenic action of ghrelin is due to changes in central dopamine receptors. MATERIALS AND METHODS: We used Sprague-Dawley rats injected with different dopamine receptor agonists, antagonists, and ghrelin. RESULTS: We demonstrate that the specific central blockade of dopamine receptor 1, 2, and 3 (D1, D2, and D3, respectively) reduces the orexigenic action of ghrelin. Similarly, specific central stimulation, either singly of dopamine receptor 1 or dopamine receptors 2 and 3 simultaneously, causes a significant decrease in ghrelin-induced food intake. Co-stimulation of all three receptors (D1, D2, and D3) also led to a marked attenuation in ghrelin-induced food intake. Importantly, the reduction in ghrelin-induced feeding was not caused by malaise or any type of behavioral alteration. CONCLUSION: Taken together, these data indicate that dopamine receptors play an important role in acute stimulation of feeding behavior induced by central injection of ghrelin.
Authors: Alfonso Abizaid; Zhong-Wu Liu; Zane B Andrews; Marya Shanabrough; Erzsebet Borok; John D Elsworth; Robert H Roth; Mark W Sleeman; Marina R Picciotto; Matthias H Tschöp; Xiao-Bing Gao; Tamas L Horvath Journal: J Clin Invest Date: 2006-10-19 Impact factor: 14.808
Authors: Ruben Nogueiras; Diego Pérez-Tilve; Christelle Veyrat-Durebex; Donald A Morgan; Luis Varela; William G Haynes; James T Patterson; Emmanuel Disse; Paul T Pfluger; Miguel López; Stephen C Woods; Richard DiMarchi; Carlos Diéguez; Kamal Rahmouni; Françoise Rohner-Jeanrenaud; Matthias H Tschöp Journal: J Neurosci Date: 2009-05-06 Impact factor: 6.167
Authors: Raphaël G P Denis; Aurélie Joly-Amado; Emily Webber; Fanny Langlet; Marie Schaeffer; Stéphanie L Padilla; Céline Cansell; Bénédicte Dehouck; Julien Castel; Anne-Sophie Delbès; Sarah Martinez; Amélie Lacombe; Claude Rouch; Nadim Kassis; Jean-Alain Fehrentz; Jean Martinez; Pascal Verdié; Thomas S Hnasko; Richard D Palmiter; Michael J Krashes; Ali D Güler; Christophe Magnan; Serge Luquet Journal: Cell Metab Date: 2015-08-13 Impact factor: 27.287
Authors: T D Müller; R Nogueiras; M L Andermann; Z B Andrews; S D Anker; J Argente; R L Batterham; S C Benoit; C Y Bowers; F Broglio; F F Casanueva; D D'Alessio; I Depoortere; A Geliebter; E Ghigo; P A Cole; M Cowley; D E Cummings; A Dagher; S Diano; S L Dickson; C Diéguez; R Granata; H J Grill; K Grove; K M Habegger; K Heppner; M L Heiman; L Holsen; B Holst; A Inui; J O Jansson; H Kirchner; M Korbonits; B Laferrère; C W LeRoux; M Lopez; S Morin; M Nakazato; R Nass; D Perez-Tilve; P T Pfluger; T W Schwartz; R J Seeley; M Sleeman; Y Sun; L Sussel; J Tong; M O Thorner; A J van der Lely; L H T van der Ploeg; J M Zigman; M Kojima; K Kangawa; R G Smith; T Horvath; M H Tschöp Journal: Mol Metab Date: 2015-03-21 Impact factor: 7.422
Authors: Panayotis K Thanos; John Hamilton; Joseph R O'Rourke; Anthony Napoli; Marcelo Febo; Nora D Volkow; Kenneth Blum; Mark Gold Journal: Oncotarget Date: 2016-04-12